RLAY Relay Therapeutics Inc

Price (delayed)

$7.91

Market cap

$975.06M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.68

Enterprise value

$875.62M

Relay Therapeutics, Inc. operates as a biotechnology company. The Company develops durgs for the treatment of cancer. Relay Therapeutics serves customers in the United States.

Highlights
RLAY's quick ratio is up by 31% since the previous quarter and by 8% year-on-year
The debt has contracted by 9% YoY
Relay Therapeutics's net income has decreased by 12% YoY but it has increased by 5% QoQ
The equity has declined by 22% year-on-year and by 3.9% since the previous quarter

Key stats

What are the main financial stats of RLAY
Market
Shares outstanding
123.27M
Market cap
$975.06M
Enterprise value
$875.62M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.24
Price to sales (P/S)
37.47
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
33.94
Earnings
Revenue
$25.8M
EBIT
-$325.98M
EBITDA
-$320.92M
Free cash flow
-$274.53M
Per share
EPS
-$2.68
Free cash flow per share
-$2.25
Book value per share
$6.37
Revenue per share
$0.21
TBVPS
$7.4
Balance sheet
Total assets
$906.96M
Total liabilities
$128.59M
Debt
$54.6M
Equity
$778.37M
Working capital
$781.05M
Liquidity
Debt to equity
0.07
Current ratio
16.39
Quick ratio
16.03
Net debt/EBITDA
0.31
Margins
EBITDA margin
-1,243.9%
Gross margin
100%
Net margin
-1,263.5%
Operating margin
-1,428.5%
Efficiency
Return on assets
-32.5%
Return on equity
-38.1%
Return on invested capital
-39%
Return on capital employed
-38.1%
Return on sales
-1,263.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

RLAY stock price

How has the Relay Therapeutics stock price performed over time
Intraday
-1.86%
1 week
-1.98%
1 month
26.97%
1 year
-57.43%
YTD
-47.05%
QTD
-5.95%

Financial performance

How have Relay Therapeutics's revenue and profit performed over time
Revenue
$25.8M
Gross profit
$25.8M
Operating income
-$368.55M
Net income
-$325.98M
Gross margin
100%
Net margin
-1,263.5%
The net margin has soared by 97% from the previous quarter and by 93% YoY
Relay Therapeutics's operating margin has soared by 96% from the previous quarter and by 92% YoY
RLAY's operating income is down by 25% year-on-year but it is up by 2.1% since the previous quarter
Relay Therapeutics's net income has decreased by 12% YoY but it has increased by 5% QoQ

Growth

What is Relay Therapeutics's growth rate over time

Valuation

What is Relay Therapeutics stock price valuation
P/E
N/A
P/B
1.24
P/S
37.47
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
33.94
The EPS has increased by 8% since the previous quarter
The P/B is 31% lower than the last 4 quarters average of 1.8
The equity has declined by 22% year-on-year and by 3.9% since the previous quarter
The stock's price to sales (P/S) is 97% less than its last 4 quarters average of 1139.6

Efficiency

How efficient is Relay Therapeutics business performance
The return on sales has surged by 97% since the previous quarter and by 93% year-on-year
The company's return on equity fell by 15% YoY
The ROA is down by 12% YoY
The return on invested capital has increased by 4.2% since the previous quarter but it has declined by 3.4% year-on-year

Dividends

What is RLAY's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RLAY.

Financial health

How did Relay Therapeutics financials performed over time
RLAY's current ratio is up by 33% since the previous quarter and by 8% year-on-year
RLAY's quick ratio is up by 31% since the previous quarter and by 8% year-on-year
The debt is 93% less than the equity
The equity has declined by 22% year-on-year and by 3.9% since the previous quarter
Relay Therapeutics's debt to equity has increased by 17% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.